Success Metrics

Clinical Success Rate
33.3%

Based on 1 completed trials

Completion Rate
33%(1/3)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Terminated
2(50%)

Phase Distribution

Ph phase_2
3
75%
Ph phase_1
1
25%

Phase Distribution

1

Early Stage

3

Mid Stage

0

Late Stage

Phase Distribution4 total trials
Phase 1Safety & dosage
1(25.0%)
Phase 2Efficacy & side effects
3(75.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

25.0%

1 of 4 finished

Non-Completion Rate

75.0%

3 ended early

Currently Active

0

trials recruiting

Total Trials

4

all time

Status Distribution
Completed(1)
Terminated(3)

Detailed Status

Terminated2
Completed1
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
0
Success Rate
33.3%
Most Advanced
Phase 2

Trials by Phase

Phase 11 (25.0%)
Phase 23 (75.0%)

Trials by Status

completed125%
withdrawn125%
terminated250%

Recent Activity

0 active trials
Showing 4 of 4
terminatedphase_2

Study to Treat Uveitis Associated Macular Edema

NCT00114062
completedphase_1

A Study in Subjects With Retinal Detachment

NCT00210067
terminatedphase_2

Study of Denufosol (INS37217) in Subjects With Rhegmatogenous Retinal Detachment

NCT00083967
withdrawnphase_2

A Study of Denufosol Tetrasodium Intravitreal Injection in Subjects With Post Cataract Extraction Macular Edema

NCT00135655

Clinical Trials (4)

Showing 4 of 4 trials
NCT00114062Phase 2

Study to Treat Uveitis Associated Macular Edema

Terminated
NCT00210067Phase 1

A Study in Subjects With Retinal Detachment

Completed
NCT00083967Phase 2

Study of Denufosol (INS37217) in Subjects With Rhegmatogenous Retinal Detachment

Terminated
NCT00135655Phase 2

A Study of Denufosol Tetrasodium Intravitreal Injection in Subjects With Post Cataract Extraction Macular Edema

Withdrawn

All 4 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
4